Gender differences in antipsychotic prescribing

References

• Alvares AP, Anderson KE, Conney AH, Kappas A. Interactions between nutritional factors and drug biotransformations in man. Proceedings of the National Academy Science of the United States of America 1976; 73: 2501–2504
   PubMed Web of Science ®Google Scholar
• Alvarez PA, Pahissa J. QT alterations in psychopharmacology: Proven candidates and suspects. Current Drug Safety 2010; 5: 97–104
   PubMedGoogle Scholar
• Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry 1999; 156: 1686–1696
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. American Journal of Psychiatry 1996; 153: 592–606
   PubMed Web of Science ®Google Scholar
• Anderson GD. Gender differences in pharmacological response. International Review of Neurobiology 2008; 83: 1–10
   PubMed Web of Science ®Google Scholar
• Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I. Journal of Women's Health and Gender Based Medicine 2002; 11: 601–615
   PubMedGoogle Scholar
• Bell RC, Farmer S, Ries R, Srebnik D. Metabolic risk factors among Medicaid outpatients with schizophrenia receiving second‐generation antipsychotics. Psychiatric Services 2009; 60: 1686–1689
   PubMed Web of Science ®Google Scholar
• Bennink R, Peeters M, Van den Maegdenbergh V, Geypens B, Rutgeerts P, De Roo M, Mortelmans L. Comparison of total and compartmental gastric emptying and antral motility between healthy men and women. European Journal of Nuclear Medicine 1998; 25: 1293–1299
   PubMedGoogle Scholar
• Bobes J, Garcia-Portilla MP, Rejas J, Hernandez G, Garcia-Garcia M, Rico-Villademoros F, Porras A. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: The results of the EIRE study. Journal of Sex and Marital Therapy 2003; 29: 125–147
   PubMed Web of Science ®Google Scholar
• Burt VK, Suri R, Altshule L, Stowe Z, Hendrick VC, Muntea E. The use of psychotropic medications during breast-feeding. American Journal of Psychiatry 2001; 158: 1001–1009
   PubMed Web of Science ®Google Scholar
• Bushe C, Yeomans D, Floyd T, Smith SM. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. Journal of Psychopharmacology 2008; 22: S56–62
   PubMedGoogle Scholar
• Christodoulou C, Kalaitzi C. Antipsychotic drug-induced acute laryngeal dystonia: Two case reports and a mini review. Journal of Psychopharmacology 2005; 19: 307–311
   PubMed Web of Science ®Google Scholar
• Cormac I, Ferriter M, Benning R, Saul C. Physical health and health risk factors in a population of long-stay psychiatric patients. The Psychiatrist 2004; 29: 18–20
   Google Scholar
• Correll. CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 2006; 45: 771–791
   PubMed Web of Science ®Google Scholar
• Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry 2008; 21: 151–156
   PubMed Web of Science ®Google Scholar
• Czekalla J, Kollack-Walker S, Beasley CM, Jr. Cardiac safety parameters of olanzapine: Comparison with other atypical and typical antipsychotics. Journal of Clinical Psychiatry 2001; 62: S35–40
   PubMed Web of Science ®Google Scholar
• Dashe JS, Twickler DM, Santos-Ramos R, McIntire DD, Ramus RM. Alpha-fetoprotein detection of neural tube defects and the impact of standard ultrasound. Amercian Journal of Obstetrics & Gynecology 2006; 195: 1623–1628
   PubMed Web of Science ®Google Scholar
• Duncan EJ, Woolson SL, Hamer RM, Dunlop BW. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. International Clinical Psychopharmacology 2009; 24: 204–213
   PubMed Web of Science ®Google Scholar
• Expert Group. Consensus summary, Schizophrenia and Diabetes 2003 Expert Consensus Meeting, Dublin, 3–4 October 2003. British Journal of Psychiatry Supplement 2004; 47: S112–114
   Google Scholar
• Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, et al. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: A systematic review and economic evaluation. Health Technology Assessment 2010; 14: 1–157
   PubMed Web of Science ®Google Scholar
• Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: Recommendations for antenatal care. Australian & New Zealand Journal of Psychiatry 2010; 44: 99–108
   PubMed Web of Science ®Google Scholar
• Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour: Literature a review. Journal of Advances in Nursing 2005; 49: 616–623
   PubMed Web of Science ®Google Scholar
• Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC, et al. Antipsychotic-induced body weight gain: Predictors and a systematic categorization of the long-term weight course. Journal of Psychiatric Research 2009; 43: 620–626
   PubMed Web of Science ®Google Scholar
• Gentile S. Clinical utilization of atypical antipsychotics in pregnancy and lactation. Annals of Pharmacotherapy 2004; 38: 265–271
   PubMed Web of Science ®Google Scholar
• Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research 2005; 80: 45–53
   PubMed Web of Science ®Google Scholar
• Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs 2004; 64: 2291–314
   PubMed Web of Science ®Google Scholar
• Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, McCreadie R. Nithsdale Schizophrenia Surveys 23: Movement disorders. 20-year review. British Journal of Psychiatry 2002; 181: 422–427
   PubMed Web of Science ®Google Scholar
• Harlow BL, Vitonis AF, Sparen P, Cnattingius S, Joffe H, Hultman CM. Incidence of hospitalization for postpartum psychotic and bipolar episodes in women with and without prior prepregnancy or prenatal psychiatric hospitalizations. Archives of General Psychiatry 2007; 64: 42–48
   PubMed Web of Science ®Google Scholar
• Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. European Heart Journal 2000; 21: 1216–1231
   PubMed Web of Science ®Google Scholar
• Hiles BW. Hyperglycemia and glucosuria following chlorpromazine therapy (letter). Journal of the American Medical Association 1956; 162: 1651
   Web of Science ®Google Scholar
• Hippisley-Cox J, Vinogradova Y, Coupland C, Parker C. Risk of malignancy in patients with schizophrenia or bipolar disorder: Nested case-control study. Archives of General Psychiatry 2007; 64: 1368–1376
   PubMed Web of Science ®Google Scholar
• Howard L, Webb R, Abel K. Safety of antipsychotic drugs for pregnant and breastfeeding women with non-affective psychosis. British Medical Journal 2004; 329: 933–934
   PubMed Web of Science ®Google Scholar
• Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. British Journal of Psychiatry 2007; 190: 129–134
   PubMed Web of Science ®Google Scholar
• Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. American Journal of Psychiatry 2004; 161: 361–363
   PubMed Web of Science ®Google Scholar
• Howes OD, Wheeler MJ, Meaney AM, O’Keane V, Fogelman I, Blake G, et al. Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. Journal of Clinical Psychopharmacology 2005; 25: 259–261
   PubMed Web of Science ®Google Scholar
• Howes OD, Wheeler MJ, Pilowsky LS, Landau S, Murray RM, Smith S. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry 2007; 68: 361–367
   PubMed Web of Science ®Google Scholar
• Jerrell JM, Bacon J, Burgis JT, Menon S. Hyperprolactinemia-related adverse events associated with antipsychotic treatment in children and adolescents. Journal of Adolescent Health 2009; 45: 70–76
   PubMed Web of Science ®Google Scholar
• Juutilainen A, Kortelainen S, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 2004; 27: 2898–2904
   PubMed Web of Science ®Google Scholar
• Kamble P, Chen H, Sherer JT, Aparasu RR. Use of antipsychotics among elderly nursing home residents with dementia in the US: An analysis of National Survey Data. Drugs Aging 2009; 26: 483–492
   PubMed Web of Science ®Google Scholar
• Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Archives of General Psychiatry 1983; 40: 1113–1117
   PubMed Web of Science ®Google Scholar
• Koga M. Clinical factors related to gains in body mass index (BMI) among patients under long-term antipsychotic treatment. Seishin Shinkeigaku Zasshi 2003; 105: 473–488
   PubMedGoogle Scholar
• Kim SH, Nikolics L, Abbasi F, Lamendola C, Link J, Reaven GM, Lindley S. Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents. Journal of Psychiatric Research 2010; 44: 493–498
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: Characterization across comparative clinical trials. Psychoneuroendocrinology 2003; 28: S69–82
   PubMed Web of Science ®Google Scholar
• Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H, van den Bosch RJ. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. Journal of Clinical Psychopharmacology 2004; 24: 56–61
   PubMed Web of Science ®Google Scholar
• Lampe JW, King IB, Li S, Grate MT, Barale KV, Chen C, et al. Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: Changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis 2000; 21: 1157–1162
   PubMed Web of Science ®Google Scholar
• Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW. Effects of gender and age on plasma levels of clozapine and its metabolites: Analyzed by critical statistics. Journal of Clinical Psychiatry 1999; 60: 36–40
   PubMed Web of Science ®Google Scholar
• Lear SA, Humphries KH, Kohli S, Chockalingam A, Frohlich JJ, Birmingham CL. Visceral adipose tissue accumulation differs according to ethnic background: Results of the Multicultural Community Health Assessment Trial (M-CHAT). American Journal of Clinical Nutrition 2007; 86: 353–359
   PubMed Web of Science ®Google Scholar
• Lear SA, Kohli S, Bondy GP, Tchernof A, Sniderman AD. Ethnic variation in fat and lean body mass and the association with insulin resistance. Journal of Clinical Endocrinology & Metabolism 2009; 94: 4696–4702
   PubMed Web of Science ®Google Scholar
• Lin CH, Chen MC, Wang SY, Lin CY. Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics. Journal of the Formosan Medical Association 2004; 103: 437–441
   PubMed Web of Science ®Google Scholar
• Liperoti R, Onder G, Landi F, Lapane KL, Mor V, Bernabei R, Gambassi G. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: A retrospective cohort study. Journal of Clinical Psychiatry 2009; 70: 1340–1347
   PubMed Web of Science ®Google Scholar
• Lipkovich I, Deberdt W, Csernansky JG, Buckley P, Peuskens J, Kollack-Walker S, et al. Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy. Journal of Psychiatric Research 2007; 41: 305–310
   PubMed Web of Science ®Google Scholar
• Lorena SL, Tinois E, Brunetto SQ, Camargo EE, Mesquita MA. Gastric emptying and intragastric distribution of a solid meal in functional dyspepsia: Influence of gender and anxiety. Journal of Clinical Gastroenterology 2004; 38: 230–236
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 2005; 80: 19–32
   PubMed Web of Science ®Google Scholar
• McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: The distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Medicine 2004; 2: 113
   Web of Science ®Google Scholar
• Meaney AM, Smith S, Howes OD, O’Brien M, Murray RM, O’Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. British Journal of Psychiatry 2004; 184: 503–508
   PubMed Web of Science ®Google Scholar
• Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics?. Clinical Pharmacokinetics 2002; 41: 329–342
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, Thompson PA. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. American Journal of Psychiatry 1997; 154: 475–482
   PubMed Web of Science ®Google Scholar
• Mendhekar DN, War L, Sharma JB, Jiloha RC. Olanzapine and pregnancy. Pharmacopsychiatry 2002; 35: 122–123
   PubMed Web of Science ®Google Scholar
• Miller LJ, Finnerty M. Family planning knowledge, attitudes and practices in women with schizophrenic spectrum disorders. Journal of Psychosomatics Obstetrics and Gynaecology 1998; 19: 210–217
   PubMed Web of Science ®Google Scholar
• Miller R, Ream G, McCormack J, Gunduz-Bruce H, Sevy S, Robinson DA. prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophrenia Research 2009; 113: 138–144
   PubMed Web of Science ®Google Scholar
• Mittendorfer B. Insulin resistance: Sex matters. Current Opinion in Clinical Nutrition and Metabolic Care 2005; 8: 367–372
   PubMed Web of Science ®Google Scholar
• Müller MJ, Regenbogen B, Sachse J, Eich FX, Härtter S, Hiemke C. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: A therapeutic drug monitoring study. Pharmacopsychiatry 2006; 39: 41–46
   PubMed Web of Science ®Google Scholar
• Munk-Olsen T, Munk Laursen T, Mendelson T, Pedersen C, Mors O, Mortensen PO. Risks and predictors of readmission for a mental disorder during the postpartum period. Archives of General Psychiatry 2009; 66: 189–195
   PubMed Web of Science ®Google Scholar
• Neighbors HW, Caldwell C, Williams DR, Nesse R, Taylor RJ, Bullard KM, et al. Race, ethnicity, and the use of services for mental disorders: Results from the National Survey of American Life. Archives of General Psychiatry 2007; 64: 485–494
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Antipsychotic medications: Metabolic and cardiovascular risk. Journal of Clinical Psychiatry 2007; 68: S8–13
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry 2002; 59: 337–345
   PubMed Web of Science ®Google Scholar
• Obias-Manno D, Scott PE, Kaczmarczyk J, Miller M, Pinnow E, Lee-Bishop L, et al. The Food and Drug Administration Office of Women's Health: Impact of science on regulatory policy. Journal of Women's Health (Larchmt) 2007; 6: 807–817
   Google Scholar
• Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L’Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. American Journal of Psychiatry 2006; 163: 1821–1825
   PubMed Web of Science ®Google Scholar
• Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Archives of General Psychiatry 2007; 64: 242–249
   PubMed Web of Science ®Google Scholar
• Paton C, Esop R, Young C, Taylor D. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatrica Scandinavica 2004; 110: 299–305
   PubMed Web of Science ®Google Scholar
• Patton SW, Misri S, Corral MR, Perry KF, Kuan AJ. Antipsychotic medication during pregnancy and lactation in women with schizophrenia: Evaluating the risk. Canadian Journal of Psychiatry 2002; 47: 959–965
   PubMed Web of Science ®Google Scholar
• Pinals DA, Malhotra AK, Missar CD, Pickar D, Breier A. Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophrenia Research 1996; 22: 215–222
   PubMed Web of Science ®Google Scholar
• Pregelj P. Neurobiological aspects of psychosis and gender. Psychiatria Danubina 2009; 21: S128–131
   PubMed Web of Science ®Google Scholar
• Raja M, Azzoni A. Novel antipsychotics and acute dystonic reactions. International Journal of Neuropsychopharmacology 2001; 4: 393–397
   PubMed Web of Science ®Google Scholar
• Raja M, Azzoni A. Sexual behaviour and sexual problems among patients with severe chronic psychoses. European Psychiatry 2003; 18: 70–76
   PubMed Web of Science ®Google Scholar
• Ramos-Ríos R, Arrojo-Romero M, Paz-Silva E, Carballal-Calvo F, Bouzón-Barreiro JL, Seoane-Prado J, et al. QTc interval in a sample of long-term schizophrenia inpatients. Schizophrenia Research 2010; 116: 35–43
   PubMed Web of Science ®Google Scholar
• Ratnayake T, Libretto SE. No complications with risperidone treatment before and throughout pregnancy and during the nursing period. Journal of Clinical Psychiatry 2002; 63: 76–77
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 1999a; 156: 544–549
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry 1999b; 56: 241–247
   PubMed Web of Science ®Google Scholar
• Rutten BP, Mill J. Epigenetic mediation of environmental influences in major psychotic disorders. Schizophrenia Bulletin 2009; 35: 1045–1056
   PubMed Web of Science ®Google Scholar
• Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. American Journal of Psychiatry 2003; 160: 284–289
   PubMed Web of Science ®Google Scholar
• Salokangas RK. Gender and the use of neuroleptics in schizophrenia. Schizophrenia Research 2004; 66: 41–49
   PubMed Web of Science ®Google Scholar
• Scandlyn MJ, Stuart EC, Rosengren RJ. Sex-specific differences in CYP450 isoforms in humans. Expert Opinion in Drug Metabolism and Toxicology 2008; 4: 413–424
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Canadian Medical Association Journal 2007; 176: 627–632
   PubMed Web of Science ®Google Scholar
• Seeman MV. Gender differences in schizophrenia. Canadian Journal of Psychiatry 1982; 27: 107–112
   PubMed Web of Science ®Google Scholar
• Smith S, Wheeler MJ, Murray R, O’Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. Journal of Clinical Psychopharmacology 2002; 22: 109–114
   PubMed Web of Science ®Google Scholar
• Smith SM, O’Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. British Journal of Psychiatry 2002; 181: 49–55
   PubMed Web of Science ®Google Scholar
• Smith S, Yeomans D, Bushe CJ, Eriksson C, Harrison T, Holmes R, et al. A well-being programme in severe mental illness. Baseline findings in a UK cohort. International Journal of Clinical Practice 2007; 61: 1971–1978
   PubMed Web of Science ®Google Scholar
• Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. American Journal of Psychiatry 1995; 152: 698–703
   PubMed Web of Science ®Google Scholar
• Tang YL, Mao P, Li FM, Li W, Chen Q, Jiang F, et al. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. British Journal of Clinical Pharmacology 2007; 64: 49–56
   PubMed Web of Science ®Google Scholar
• Tang YL, Gillespie CF, Epstein MP, Mao PX, Jiang F, Chen Q, et al. Gender differences in 542 Chinese inpatients with schizophrenia. Schizophrenia Research 2007; 97: 88–96
   PubMed Web of Science ®Google Scholar
• Taylor D, Young C, Mohamed R, Paton C, Walwyn R. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. Journal of Psychopharmacology 2005; 19: 182–186
   PubMed Web of Science ®Google Scholar
• Taylor TM, O’Toole MS, Ohlsen RI, Walters J, Pilowsky LS. Safety of quetiapine during pregnancy. American Journal of Psychiatry 2003; 160: 588–589
   PubMed Web of Science ®Google Scholar
• Thanvi B, Treadwell S. Drug induced Parkinsonism: A common cause of Parkinsonism in older people. Postgraduate Medical Journal 2009; 85: 322–326
   PubMed Web of Science ®Google Scholar
• Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. American Journal of Psychiatry 1968; 124: 978–982
   PubMed Web of Science ®Google Scholar
• Usall J, Suarez D, Haro JM, SOHO Study Group. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Research 2007; 153: 225–231
   PubMed Web of Science ®Google Scholar
• Valdimarsdóttir U, Hultman C, Harlow B, Cnattingius S, Sparén P. Psychotic illness in first-time mothers with no previous psychiatric hospitalizations: A population-based study. Public Library of Science: Medicine 2009; 6: e13
   Google Scholar
• van Harten PN, Kahn RS. Tardive dystonia. Schizophrenia Bulletin 1999; 25: 741–748
   PubMed Web of Science ®Google Scholar
• van Os J, Walsh E, van Horn E, Tattan T, Bale R, Thompson SG. Tardive dyskinesia in psychosis: Are women really more at risk? UK700 Group. Acta Psychiatrica Scandinavica 1999; 99: 288–293
   PubMed Web of Science ®Google Scholar
• Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first‐episode psychosis. Journal of Clinical Psychiatry 2009; 70: 997–1000
   PubMed Web of Science ®Google Scholar
• Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, et al. Risk of recurrence in women with bipolar disorder during pregnancy: Prospective study of mood stabilizer discontinuation. American Journal of Psychiatry 2007; 164: 1817–1824
   PubMed Web of Science ®Google Scholar
• Wang PS, Gilman SE, Guardino M, Christiana JM, Morselli PL, Mickelson K, Kessler RC. Initiation of and adherence to treatment for mental disorders: Examination of patient advocate group members in 11 countries. Medical Care 2000; 38: 926–936
   PubMed Web of Science ®Google Scholar
• Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, Avorn J. Dopamine antagonists and the development of breast cancer. Archives of General Psychiatry 2002; 59: 1147–1154
   PubMed Web of Science ®Google Scholar
• Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New England Journal of Medicine 2005; 353: 2335–2341
   PubMed Web of Science ®Google Scholar
• Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breast-feeding. American Journal of Psychiatry 1996; 153: 1132–1137
   PubMed Web of Science ®Google Scholar
• Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003; 38: 978–988
   PubMed Web of Science ®Google Scholar
• Yoshida K, Smith B, Craggs M, Kumar R. Neuroleptic drugs in breast-milk: A study of pharmacokinetics and of possible adverse effects in breast-fed infants. Psychological Medicine 1998; 28: 81–91
   PubMed Web of Science ®Google Scholar
• Yoshida K, Yamashita H. Treatment strategy for women with puerperal psychiatric disorders - Psychopharmaco-therapy and its impact on fetus and breast-fed infants. Seishin Shinkeigaku Zasshi 2003; 105: 1136–1144
   PubMedGoogle Scholar
• Zhang XY, Chen da C, Qi LY, Wang F, Xiu MH, Chen S, et al. Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia. Psychopharmacology (Berlin) 2009; 205: 647–654
   PubMed Web of Science ®Google Scholar